MAML2 and Poroma: Recurrent YAP1-MAML2 fusions have been reported in poroma and porocarcinomas, pediatric NF2‐wildtype meningioma, composite and retiform hemangioendothelioma, glioblastoma, nasopharyngeal carcinoma and ovarian cancer cell lines (19–24).